Figure 7.

Combined therapy with lanthanum carbonate and calcium (Ca) carbonate for hyperphosphatemia decreases serum FGF23 levels independently of Ca and parathyroid hormone (PTH). The horizontal bar in each box indicates the median value. Upper and lower borders of the box are the 25th and 75th percentiles, respectively. Maximum and minimum values are shown by the vertical error bars. The significant 40% reduction of the circulating intact FGF23 level from baseline was observed after week 8 and week 16 of combined therapy of lanthanum carbonate and Ca carbonate therapy. On the other hand, the intact PTH level did not show any significant change within 16 weeks.

Note: Reproduced from Shigematsu T, Negi S; for the COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant. 2012;27(3):1050–1054,32 with permission from Oxford Journals.